Literature DB >> 12643614

High prevalence of non-organ-specific autoantibodies in hepatitis C virus-infected cirrhotic patients from southern Italy.

Giovanni Squadrito1, Marcello Previti, Marco Lenzi, Enrico Pagano Le Rose, Gaia Caccamo, Tea Restuccia, Enrico Di Cesare, Teresa Pollicino, Giovanni Raimondo.   

Abstract

Non-organ-specific autoantibodies (NOSAs) are frequently found in patients with hepatitis C virus (HCV) chronic infection. Genetics is likely involved in the development of autoimmune reactivities, and differences in the prevalence of HCV-related autoantibodies among populations of various geographic areas should be expected. We evaluated the prevalence and the clinical impact of NOSAs in a series of HCV-infected patients from southern Italy. We studied 283 consecutive anti-HCV positive patients (162 men, 121 women, mean age 54.5 +/- 13.5 years), 94 of whom were cirrhotics and 189 noncirrhotics. Serum from each patient and from 41 hepatitis B surface antigen (HBsAg)-positive/anti-HCV negative control subjects were tested (dilution 1:40) for autoantibodies by indirect immunofluorescence. Qualitative/quantitative HCV-RNA determinations were also performed. The prevalence of NOSAs was significantly higher in anti-HCV-positive subjects than in HBsAg-positive patients (P < 0.006). Autoantibodies were significantly associated with both cirrhosis (P < 0.0001) and older age (P < 0.05). No significant association between NOSAs and either female gender or virological parameters (HCV-RNA positivity, viral load, and genotype) was found. In conclusion, the autoantibody positivity in HCV-infected patients from southern Italy is significantly related to cirrhosis and older age, although its general prevalence is similar to that reported in populations from the north of the country.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12643614     DOI: 10.1023/a:1021991813586

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  41 in total

Review 1.  Natural history of chronic hepatitis C.

Authors:  L Pagliaro; V Peri; C Linea; C Cammà; M Giunta; S Magrin
Journal:  Ital J Gastroenterol Hepatol       Date:  1999 Jan-Feb

2.  Cryoglobulinemia in Japanese patients with chronic hepatitis C virus infection: host genetic and virological study.

Authors:  A Nagasaka; T Takahashi; T Sasaki; K Takimoto; K Miyashita; M Nakamura; O Wakahama; S Nishikawa; A Higuchi
Journal:  J Med Virol       Date:  2001-09       Impact factor: 2.327

3.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

4.  Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.

Authors:  G Squadrito; F Leone; M Sartori; B Nalpas; P Berthelot; G Raimondo; S Pol; C Bréchot
Journal:  Gastroenterology       Date:  1997-08       Impact factor: 22.682

5.  High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy.

Authors:  A Tran; J F Quaranta; S Benzaken; V Thiers; H T Chau; P Hastier; D Regnier; G Dreyfus; C Pradier; J L Sadoul
Journal:  Hepatology       Date:  1993-08       Impact factor: 17.425

6.  Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis.

Authors:  A J Czaja; M P Manns; H A Homburger
Journal:  Gastroenterology       Date:  1992-10       Impact factor: 22.682

7.  Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis.

Authors:  M W Fried; J O Draguesku; M Shindo; L H Simpson; S M Banks; J H Hoofnagle; A M Di Bisceglie
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

8.  The role of autoimmunity in hepatitis C infection.

Authors:  K H Meyer zum Büschenfelde; A W Lohse; G Gerken; U Treichel; H F Löhr; H Mohr; A Grosse; H P Dienes
Journal:  J Hepatol       Date:  1995       Impact factor: 25.083

9.  Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection.

Authors:  V S Wong; W Egner; T Elsey; D Brown; G J Alexander
Journal:  Clin Exp Immunol       Date:  1996-04       Impact factor: 4.330

10.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

View more
  7 in total

1.  Anti-C1q antibodies in hepatitis C virus infection.

Authors:  D Saadoun; S Sadallah; M Trendelenburg; N Limal; D Sene; J C Piette; J A Schifferli; P Cacoub
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

2.  Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha.

Authors:  Stephan Gehring; Ulrike Kullmer; Sabine Koeppelmann; Patrick Gerner; Philip Wintermeyer; Stefan Wirth
Journal:  World J Gastroenterol       Date:  2006-09-28       Impact factor: 5.742

3.  Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study.

Authors:  Nikolaos K Gatselis; Sarah P Georgiadou; Nikolaos Tassopoulos; Kalliopi Zachou; Christos Liaskos; Angelos Hatzakis; Georgios N Dalekos
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

4.  Celiac disease and non-organ-specific autoantibodies in patients with chronic hepatitis C virus infection.

Authors:  Caterina Ruggeri; Agata Tiziana La Masa; Stefania Rudi; Giovanni Squadrito; Giuseppe Di Pasquale; Sergio Maimone; Gaia Caccamo; Salvatore Pellegrino; Giovanni Raimondo; Giuseppe Magazzù
Journal:  Dig Dis Sci       Date:  2008-01-31       Impact factor: 3.199

Review 5.  Autoantibodies in chronic hepatitis C: A clinical perspective.

Authors:  Janaína Luz Narciso-Schiavon; Leonardo de Lucca Schiavon
Journal:  World J Hepatol       Date:  2015-05-18

6.  The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection.

Authors:  E Orge; A Cefle; Ayten Yazici; N Gürel-Polat; S Hulagu
Journal:  Rheumatol Int       Date:  2009-06-23       Impact factor: 2.631

7.  Hepatitis C virus NS4 protein impairs the Th1 polarization of immature dendritic cells.

Authors:  A Takaki; M Tatsukawa; Y Iwasaki; K Koike; Y Noguchi; H Shiraha; K Sakaguchi; E Nakayama; K Yamamoto
Journal:  J Viral Hepat       Date:  2009-10-04       Impact factor: 3.728

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.